Skip to main content
α
中文

AI-generated · Based on company filings and platform data · Not investment advice

Earnings Brief MRK

Merck (MRK) Q3 2026 Earnings Brief: Revenue $18.09B, +4.7% YoY

Released Oct 29, 2026 (ET)

Quarter: Q3 2026, period ended 2026-09-30; released 2026-10-29 (ET).

In one line: Merck's revenue in the third quarter of 2026 was US$18.08 billion, with adjusted earnings per share of US$2.49, exceeding analysts' consensus expectations by 19.6%.

Key numbers

MetricThis quarterNote
Revenue$18.09BYoY +4.7%
Adj. EPS vs consensus$2.49 vs $2.08Beat (+19.6%)
GAAP diluted EPS$2.04Different basis from consensus
Net margin28.0%Net income $5.07B
Next-quarter EPS consensus$1.7519 analysts; revenue consensus $16.28B

Three things to know

1. Acquisition of Terns Pharmaceuticals

In May 2026, Merck acquired Terns Pharmaceuticals, a clinical-stage anti-cancer company, for US$6.8 billion to obtain its drug candidate MK-4208. The transaction was accounted for as an asset acquisition, and the company recognized $5.7 billion in research and development expenses in the first nine months, mainly expenses for ongoing research projects without alternative uses.

2. Acquisition of Cidara Biotech

In January 2026, Merck acquired Cidara Therapeutics for US$9.2 billion to obtain its anti-influenza drug candidate MK-1406. The transaction was accounted for as an asset acquisition, and the company recognized $9 billion in research and development expenses in the first nine months, mainly expenses for ongoing research projects without alternative uses.

3. Licensing agreement with SciBrunch

In September 2026, Merck reached an exclusive licensing agreement with SciBrunch and obtained the global development, production and commercialization rights of the KRAS G12D inhibitor MK-2690 (SPR2015). The company recognized US$400 million in research and development expenditures in this quarter and the first nine months as a down payment, which is expected to be paid in the fourth quarter.

Market reaction

Results were released on 2026-10-29 (ET). From the last pre-report close (2026-10-28, $140.93) to the close of the first session after the report (2026-10-30, $149.52), the stock moved +6.10%. The report-day close was $146.33; the next session closed +2.18% from it (for after-hours releases, this leg better reflects the reaction to the report).

What to watch next

  • Pay attention to whether the revenue in the fourth quarter 2026 financial report is in line with the consensus estimate of $16.28 billion.
  • Observe whether R&D investment in the fourth quarter of 2026 continues at the level of the first nine months.
  • Watch for management's updates on the clinical progress of MK-4208 and MK-1406 in subsequent disclosures.
  • Next report date (platform calendar): 2027-02-02

Sources

  • Financials: fundamentals-svc (EDGAR filings, analyst consensus)
  • Prices: fundamentals-svc /v1/candles-ondemand
  • MD&A source: 10-Q (filed 2026-11-04)
  • Company press release (8-K): SEC EDGAR

Read the Merck (MRK) stock report →

← All earnings briefs